Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Oct;66(10):e27900.
doi: 10.1002/pbc.27900. Epub 2019 Jul 5.

Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

François Doz  1 , Franco Locatelli  2 , André Baruchel  3 , Nicolas Blin  4 , Barbara De Moerloose  5 , Didier Frappaz  6 , Michael Dworzak  7 , Matthias Fischer  8 , Jan Stary  9 , Rene Fuertig  10 , Kathrin Riemann  11 , Tillmann Taube  12 , Dirk Reinhardt  13
Affiliations
Clinical Trial

Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors

François Doz et al. Pediatr Blood Cancer. 2019 Oct.

Abstract

Background: Volasertib induces mitotic arrest and apoptosis by targeting Polo-like kinases. In this phase I dose-escalation study, the maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary efficacy of volasertib were determined in pediatric patients.

Methods: Patients aged 2 to <18 years with relapsed/refractory acute leukemia/advanced solid tumors (ST) without available effective treatments were enrolled-cohort C1 (aged 2 to <12 years); cohort C2 (aged 12 to <18 years). The patients received volasertib intravenously (starting dose: 200 mg/m2 body surface area on day 1, every 14 days). The primary endpoint was the pediatric MTD for further development.

Results: Twenty-two patients received treatment (C1: leukemia, n = 4; ST, n = 8; C2: leukemia, n = 3; ST, n = 7). No dose-limiting toxicities (DLTs) occurred up to 300 mg/m2 volasertib in C1; two patients in C2, at 250 mg/m2 volasertib, had DLTs in cycle 1, one of which led to death; therefore, the MTD of volasertib in C2 was 200 mg/m2 . The most common grade 3/4 adverse events (all patients) were febrile neutropenia, thrombocytopenia, and neutropenia (41% each). Stable disease (SD) was the best objective response (leukemia, n = 5; ST, n = 2); the duration of SD was short in all patients, except in one with an ST. PK profiles were generally comparable across dose groups and were consistent with those in adults.

Conclusion: The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.

Keywords: PLK inhibitor; leukemia; pediatric cancers; pharmacokinetics; phase I; solid tumors; volasertib.

PubMed Disclaimer

References

REFERENCES

    1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
    1. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025-2029.
    1. National Cancer Institute. Cancer in children and adolescents fact sheet. 2017. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-... [Accessed December 18, 2018].
    1. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(14):1663-1669.
    1. Takaki T, Trenz K, Costanzo V, Petronczki M. Polo-like kinase 1 reaches beyond mitosis-cytokinesis, DNA damage response, and development. Curr Opin Cell Biol. 2008;20(6):650-660.

Publication types

LinkOut - more resources